Showing 5041-5050 of 7117 results for "".
- Upadacitinib Shows Strong Hair Regrowth in Alopecia Areatahttps://practicaldermatology.com/news/upadacitinib-shows-strong-hair-regrowth-in-alopecia-areata/2486456/Upadacitinib demonstrated robust efficacy in both adolescents and adults with severe alopecia areata (AA), with particularly strong responses observed in younger patients, according to a subgroup analysis of two Phase 3 trials presented by Melinda Gooderham, MD, MSc, at the American Academy of De
- Rezpegaldesleukin Shows Promise in Alopecia Areata in Phase 2b Trialhttps://practicaldermatology.com/news/rezpegaldesleukin-shows-promise-in-alopecia-areata-in-phase-2b-trial/2486426/Rezpegaldesleukin, an IL-2 pathway agonist designed to expand regulatory T cells (Tregs), demonstrated clinical efficacy and a favorable safety profile in patients with severe-to-very-severe alopecia areata (AA), according to Phase 2b REZOLVE-AA data presented by David Rosmarin, MD, at the Americ
- Zumilokibart Shows Rapid Symptom Relief in Atopic Dermatitishttps://practicaldermatology.com/news/zumilokibart-shows-rapid-symptom-relief-in-atopic-dermatitis/2486425/Zumilokibart (APG777), a half-life–extended anti–IL-13 monoclonal antibody, demonstrated rapid and sustained improvements in symptoms and quality of life in patients with moderate-to-severe atopic dermatitis (AD), according to Phase 2 APEX Part A results presented by Emma Guttman-Yassky, MD, PhD,
- AAD Updates Systemic Therapy Guidelines for Adult ADhttps://practicaldermatology.com/news/aad-updates-systemic-therapy-guidelines-for-adult-atopic-dermatitis/2486418/The American Academy of Dermatology (AAD) has issued an interim update to its clinical practice guidelines for systemic treatment of moderate to severe atopic dermatitis (AD) in adults, reflecting the rapid expansion of evidence supporting targeted therapies. The u
- Litifilimab Advances CLE Treatment With Positive Phase 2 Datahttps://practicaldermatology.com/news/litifilimab-advances-cle-treatment-with-positive-phase-2-data/2486419/Late-breaking data from the Phase 2 AMETHYST Part A trial presented at the American Academy of Dermatology (AAD) 2026 Annual Meeting show that litifilimab, a monoclonal antibody targeting blood dendritic cell antigen 2 (BDCA2), improved disease activity in patients with cutaneous lupus erythemato
- Study: Dermatologists Rarely Prescribe GLP-1 Agents in Psoriasis, HS Cohorthttps://practicaldermatology.com/news/study-dermatologists-rarely-prescribe-glp-1-agents-in-psoriasis-hs-cohort/2486411/A new retrospective review identified a significant gap in care between eligibility for glucagon-like peptide-1 receptor agonists (GLP-1RAs) and real-world utilization among patients with psoriasis and hidradenitis suppurativa (HS).
- ILDS, WHO Launch Global Dermatology Training Hub to Address Care Gapshttps://practicaldermatology.com/news/ilds-who-launch-global-dermatology-training-hub-to-address-care-gaps/2486380/The International League of Dermatological Societies (ILDS), in collaboration with the World Health Organization (WHO), has launched the ILDS Dermatology Training Hub, a free online platform aimed at expanding access to dermatology education worldwide. The initiati
- Study: Potential Link Between Lesional IgG Autoantibodies and HS Disease Severityhttps://practicaldermatology.com/news/study-suggests-potential-link-between-lesional-igg-autoantibodies-and-hs-disease-severity/2486348/A small biopsy-based study in the Journal of Investigative Dermatology Innovations adds to emerging evidence that humoral immunity may contribute to hidradenitis suppurativa (HS) pathobiology. Investigators analyzed
- Lutikizumab Improves Clinical Response Rates in Moderate to Severe HS: Analysishttps://practicaldermatology.com/news/lutikizumab-shows-promise-in-hs-after-anti-tnf-failure-in-phase-2-trial/2486330/In a phase 2, double-blind, placebo-controlled randomized clinical trial, lutikizumab demonstrated efficacy signals in adults with moderate to severe hidradenitis suppurativa (HS) who had previously experienced anti–tumor necrosis factor (TNF) therapy failure.
- Review: Dermoscopic Patterns May Improve Differentiation of Acral Melanoma and Nevihttps://practicaldermatology.com/news/review-dermoscopic-patterns-may-improve-differentiation-of-acral-melanoma-and-nevi/2486062/A systematic review and meta-analysis in JAMA Dermatology provides updated evidence on dermoscopic features that differentiate acral lentiginous melanoma (ALM) from benign acral nevi. Investigators searched Embase, P